Patent ID: 9545407
Date: 2017-01-17
CPC Classifications: A61K,A61P

Claim:
1. A solid dispersion formulation, wherein the formulation comprises a) about 49 to about 51% w/w of 50% active spray-dried ibrutinib, wherein ibrutinib is a compound of formula (I), b) about 16 to about 18% w/w of lactose, c) about 24 to about 26% w/w of microcrystalline cellulose, d) about 5 to about 7% w/w of croscarmellose sodium, e) about 0.8 to about 1.2% w/w of colloidal silicon dioxide, and f) about 0.2 to about 0.8% w/w of magnesium stearate; and wherein the 50% active spray-dried ibrutinib is a spray-dried ibrutinib composition comprising about 50% w/w of ibrutinib dispersed into a polymer matrix; and the polymer in the polymer matrix is hydroxypropyl methyl cellulose acetate succinate (HPMCAS).